ArticleInfection and drug resistance2022
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clarithromycin-resistant Helicobacter pylori in Africa: a systematic review and meta-analysis.Antimicrobial resistance and infection control · 2025Pooled it
- Levofloxacin versus moxifloxacin in nitazoxanide-based quadruple therapy as a first-line treatment for Helicobacter pylori infection: NILE, a randomized, comparative, multicenter study.Scientific reports · 2026Trial
- Vonoprazan-based therapy versus standard regimen for Helicobacter pylori infection management in Egypt: an open-label randomized controlled trial.Scientific reports · 2025Trial
- Levofloxacin and Rifampin Resistance inAntibiotics (Basel, Switzerland) · 2026Article
- Novel anti-virulence strategy againstFrontiers in microbiology · 2026Article
- Phenotypic and Genotypic Characterization of Antimicrobial Resistance inInternational journal of microbiology · 2026Article
- Synergistic potentiation of antibiotics by chamomile phytochemicals against multidrug-resistant Helicobacter pylori.Gut pathogens · 2025Article
- Article
- Comparative Efficacy of Azithromycin and Clarithromycin in the Management of Helicobacter pylori Infection.Cureus · 2024Article
- Molecular characterization of Helicobacter pylori isolated from Nile Tilapia (Oreochromis niloticus) and fish handlers.BMC veterinary research · 2023Article
- Treatment ofHeliyon · 2023Review
- Mutations Related to Antibiotics Resistance inAntibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Methods: This cross-sectional study included 134 adult patients with upper gastrointestinal (GI) complaints. Patients with a history of PPI during the last 2 weeks or antibiotics during the last 4 weeks before endoscopy were excluded. Upper GI endoscopies were performed and biopsies were collected for histopathology and Results: The Conclusion: In Egyptian patients,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.